ABSTRACT NUMBER: ESOC2026A2277 DIAGNOSTIC VALUE OF SERUM BRAIN-DERIVED NEUROTROPHIC FACTOR IN ACUTE ISCHEMIC STROKE: A CROSS-SECTIONAL STUDY

Abstract Background and aims Stroke is a leading cause of mortality and disability worldwide. Although CT and MRI are the gold standards for stroke diagnosis, their limited accessibility and reduced sensitivity in the hyperacute phase necessitate complementary biomarkers. Brain-derived neurotrophic factor (BDNF), a key regulator of neuronal survival and neuroplasticity, has been proposed as a potential diagnostic marker in acute ischemic stroke (AIS). Methods This cross-sectional diagnostic accuracy study was conducted at Imam Reza Hospital, Tabriz, Iran. Forty-nine participants were enrolled, including 22 patients with CT-confirmed AIS and 27 healthy controls. Blood samples were collected at admission prior to treatment initiation. Serum BDNF levels were measured using ELISA. Diagnostic performance was assessed using receiver operating characteristic (ROC) curve analysis, with the optimal cutoff determined by the Youden Index. The study protocol was approved by the Ethics Committee of Tabriz University of Medical Sciences (IR.TBZMED.REC.1403.709). Results Serum BDNF levels were significantly lower in AIS patients compared with controls (median [IQR]: 0.18 [1.54] vs. 0.95 [2.24] ng/mL; p = 0.02). ROC analysis demonstrated moderate diagnostic accuracy (AUC = 0.688; 95% CI: 0.534–0.842; p = 0.029). A cutoff value of <0.250 ng/mL yielded a sensitivity of 79.2% and a specificity of 59.1%. Conclusions Serum BDNF levels are reduced in acute ischemic stroke and show moderate diagnostic accuracy. While insufficient as a standalone diagnostic tool, BDNF may serve as a complementary biomarker for early stroke detection. Larger studies are warranted. Conflict of interest Afshin Moradi: nothing to disclose. Asal Ebrahimian: nothing to disclose. Amirreza Naseri: nothing to disclose. Samad Shams Vahdati: nothing to disclose. Sarvin Sanaie: nothing to disclose. Mehdi Yousefi: nothing to disclose. Shayan Ahadi: nothing to disclose. Behnaz Ahmadi: nothing to disclose.

Authors

Institutions

Publication Details

Journal
European Stroke Journal
Published
2026-05-01
DOI
https://doi.org/10.1093/esj/aakag023.1782
Primary Topic
Acute Ischemic Stroke Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

ABSTRACT NUMBER: ESOC2026A2277 DIAGNOSTIC VALUE OF SERUM BRAIN-DERIVED NEUROTROPHIC FACTOR IN ACUTE ISCHEMIC STROKE: A CROSS-SECTIONAL STUDY

Amirreza Naseri, Samad Shams Vahdati, Sarvin Sanaie, Asal Ebrahimian et al.
European Stroke Journal
Acute Ischemic Stroke Management
article

ABSTRACT NUMBER: ESOC2026A2277 DIAGNOSTIC VALUE OF SERUM BRAIN-DERIVED NEUROTROPHIC FACTOR IN ACUTE ISCHEMIC STROKE: A CROSS-SECTIONAL STUDY

Amirreza Naseri, Samad Shams Vahdati, Sarvin Sanaie, Asal Ebrahimian, Behnaz Ahmadi, Afshin Moradi, Shayan Ahadi, Mehdi Yousefi
article en

Abstract

Abstract Background and aims Stroke is a leading cause of mortality and disability worldwide. Although CT and MRI are the gold standards for stroke diagnosis, their limited accessibility and reduced sensitivity in the hyperacute phase necessitate complementary biomarkers. Brain-derived neurotrophic factor (BDNF), a key regulator of neuronal survival and neuroplasticity, has been proposed as a potential diagnostic marker in acute ischemic stroke (AIS). Methods This cross-sectional diagnostic accuracy study was conducted at Imam Reza Hospital, Tabriz, Iran. Forty-nine participants were enrolled, including 22 patients with CT-confirmed AIS and 27 healthy controls. Blood samples were collected at admission prior to treatment initiation. Serum BDNF levels were measured using ELISA. Diagnostic performance was assessed using receiver operating characteristic (ROC) curve analysis, with the optimal cutoff determined by the Youden Index. The study protocol was approved by the Ethics Committee of Tabriz University of Medical Sciences (IR.TBZMED.REC.1403.709). Results Serum BDNF levels were significantly lower in AIS patients compared with controls (median [IQR]: 0.18 [1.54] vs. 0.95 [2.24] ng/mL; p = 0.02). ROC analysis demonstrated moderate diagnostic accuracy (AUC = 0.688; 95% CI: 0.534–0.842; p = 0.029). A cutoff value of <0.250 ng/mL yielded a sensitivity of 79.2% and a specificity of 59.1%. Conclusions Serum BDNF levels are reduced in acute ischemic stroke and show moderate diagnostic accuracy. While insufficient as a standalone diagnostic tool, BDNF may serve as a complementary biomarker for early stroke detection. Larger studies are warranted. Conflict of interest Afshin Moradi: nothing to disclose. Asal Ebrahimian: nothing to disclose. Amirreza Naseri: nothing to disclose. Samad Shams Vahdati: nothing to disclose. Sarvin Sanaie: nothing to disclose. Mehdi Yousefi: nothing to disclose. Shayan Ahadi: nothing to disclose. Behnaz Ahmadi: nothing to disclose.

European Stroke JournalVol. 11(Supplement_1)
Tabriz University of Medical Sciences (IR)
Good health and well-being
Openalex Percentile: Top 9%
Acute Ischemic Stroke Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.